Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. (Symbol: BEAT) is a cutting-edge medical technology company that focuses on developing and commercializing high-resolution ambulatory Electrocardiogram (ECG) solutions. These solutions are designed to detect and monitor cardiac diseases outside traditional healthcare settings, providing critical diagnostic capabilities in a more accessible manner.
HeartBeam's flagship product is an innovative, credit card-sized ECG device that is diagnostically equivalent to a cardiologist reading a patient's 12-lead ECG and examining the patient. This compact device integrates seamlessly with a cloud-based diagnostic expert system, offering a comprehensive and user-friendly solution for cardiac monitoring.
Notably, studies designed by Harvard Medical School faculty have demonstrated that HeartBeam's technology performs on par with, or better than, world-class cardiologists in diagnosing heart attacks. The system features personalized diagnostic thresholds and unique ECG markers that help pinpoint the location of a heart attack on a 3D heart model, enhancing the accuracy and depth of diagnostic information provided to healthcare professionals.
One of the key components of HeartBeam's technology is the iCardiologist application, which uses artificial intelligence and machine learning to continually improve its diagnostic accuracy and predictive capabilities. This application aids cardiologists by providing detailed patient analysis, thereby supporting more informed and timely medical decisions.
HeartBeam has developed a proprietary and patented Vector Electrocardiography (VECG) technology platform, which is the cornerstone of its high-resolution ECG solutions. The company has validated this platform and is in the process of seeking U.S. Food and Drug Administration (FDA) clearance for its initial telehealth products.
With its innovative approach and proven technology, HeartBeam is poised to make significant strides in the field of cardiac care, offering practical solutions that can be utilized outside traditional healthcare environments, thereby broadening access to critical diagnostic tools and improving patient outcomes.
Latest News: Source: HeartBeam, Inc.
- ------
- ------
- ------
HeartBeam (NASDAQ: BEAT) announced its participation in the JP Morgan 2025 Annual Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco. The company's leadership will be available for meetings to discuss their recently FDA-cleared HeartBeam system for comprehensive arrhythmia assessment.
The breakthrough device, the first of its kind to receive FDA clearance, features a credit card-sized form factor and cable-free design. It uniquely captures ECG signals from three distinct directions, providing actionable heart health information. The company plans to implement an Early Access Program and aims to leverage AI technology to analyze longitudinal ECG data, potentially predicting cardiac conditions before symptom onset.
HeartBeam (NASDAQ: BEAT) has received FDA 510(k) clearance for its innovative cardiac monitoring system. The device is the first cable-free, credit card-sized ECG that captures heart signals from three distinct directions, enabling high-fidelity data collection. When patients experience symptoms, they can use the HeartBeam app to record a 30-second ECG, which is then cloud-processed and sent to physicians for review.
The company plans to launch an Early Access Program and is developing future advances including: synthesized 12-lead ECG capabilities, AI-based classification algorithms for improved arrhythmia detection, and heart attack detection features. A study in JACC: Advances demonstrated the technology's high accuracy (95% AUC) in identifying coronary occlusions, comparable to standard 12-lead ECGs.
HeartBeam (NASDAQ: BEAT) presented positive results from two studies at the American Heart Association's Scientific Sessions, validating its vector-based cardiac monitoring technology. The first study, an 80-patient pilot, demonstrated excellent agreement between HeartBeam's synthesized 12-lead ECG and standard ECGs for arrhythmia detection, showing 94% sensitivity and 100% specificity. The second study validated a novel algorithm for acute coronary syndrome risk assessment, matching expert physician evaluations. The company's technology utilizes a portable, credit card-sized device capable of synthesizing 12-lead ECGs, currently under FDA review.
HeartBeam (NASDAQ: BEAT) reported Q3 2024 financial results, highlighting progress on its cardiac care technology. The company's FDA 510(k) submission for the HeartBeam system is under active review, with successful responses to FDA questions. Financial results show R&D expenses of $2.9M vs $1.6M in Q3 2023, and net loss of $5.0M vs $3.5M in Q3 2023. Cash position stands at $5.8M as of September 30, 2024. Key management appointments include Robert Eno as CEO, Dr. Branislav Vajdic as President, Tim Cruickshank as CFO, and Dr. Lance Myers as Chief AI Scientist.
HeartBeam (NASDAQ: BEAT) has announced its upcoming Q3 2024 earnings conference call scheduled for November 7, 2024, at 4:30 p.m. Eastern time. The call will feature CEO Robert Eno, Founder and President Branislav Vajdic, and CFO Timothy Cruickshank discussing third quarter results, regulatory updates, ongoing initiatives, and anticipated milestones. A press release with detailed results will be issued before the call. The presentation will be accessible via webcast and the company's investor relations website. A replay will be available until February 7, 2025.
HeartBeam (NASDAQ: BEAT) has been named a Rising Star in the 'Home Health Diagnostic' category at the 2024 Digital Health Hub Foundation Awards. The recognition was presented during the HLTH global healthcare conference for the company's innovative vector-based technology that captures heart electrical signals in three dimensions. The company's first application is a cable-free, credit card-sized device designed to synthesize a 12-lead ECG, currently under FDA review. HeartBeam holds 13 US patents and 4 international patents for its technology, which aims to provide comprehensive cardiac insights by leveraging AI analysis.
HeartBeam (NASDAQ: BEAT) has appointed Robert Eno as Chief Executive Officer, effective October 21, 2024. Eno, who joined as President in January 2023, will lead the company's efforts to secure FDA 510(k) clearance for its vector-based technology and prepare for commercialization. Founder and current CEO Branislav Vajdic will transition to the role of President, focusing on innovation, R&D, and advancing AI applications.
HeartBeam's core technology captures the heart's electrical signals in three dimensions, providing total heart intelligence. The company's first application is a cable-free, credit card-sized device designed to synthesize a 12-lead ECG, currently under FDA review. HeartBeam holds 13 U.S. patents and 4 international patents for its technology.
Eno brings over 30 years of experience in developing go-to-market strategies for breakthrough medical products. He previously served as CEO of Preview Medical and held senior roles at HeartFlow, OptiMedica, and other medical technology companies.
HeartBeam (NASDAQ: BEAT) has appointed Dr. Lance Myers as Chief AI Scientist to drive innovation in its cardiac care technology. Dr. Myers, formerly Head of Data Science at Verily (Google Life Sciences), will guide AI application to HeartBeam's core technology. The company's vector-based approach combined with AI has shown equivalent performance to a 12-lead ECG and improved detection of atrial flutter over single-lead ECG.
HeartBeam's technology captures heart signals in three dimensions, with its first application being a cable-free, credit card-sized device capable of synthesizing a 12-lead ECG. The system is under FDA review. The company aims to leverage AI for improved diagnostic accuracy and personalized cardiac care, analyzing longitudinal data from patient device usage.
HeartBeam (NASDAQ: BEAT) has appointed Timothy Cruickshank as its new Chief Financial Officer, effective immediately. Cruickshank brings over 15 years of public company experience, focusing on growing businesses with disruptive technologies. He succeeds Richard Brounstein, who retired in February.
HeartBeam has developed a cable-free, credit card-sized device that captures the heart's electrical signals in three dimensions, capable of synthesizing a 12-lead ECG. The company's first 510(k) submission for this proprietary technology is currently under FDA review. HeartBeam holds 13 US patents and 4 international patents supporting the technology.
Cruickshank, 43, previously served as CFO at ImpediMed, where he led the company's transformation from a traditional medical device company to a medical technology company with a high-margin SaaS business model.
HeartBeam (NASDAQ: BEAT) reported Q2 2024 results, highlighting progress on its HeartBeam AIMIGo™ System. Key developments include:
1. FDA review of AIMIGo 510(k) submission ongoing, with most questions resolved.
2. Completed enrollment for VALID-ECG clinical study.
3. Presented new data on HeartBeam AI at EHRA and HRS conferences.
4. Won 'Best New ECG Technology Solution' award.
5. Added to Russell Microcap® Index.
Financial results: R&D expenses $2.8M, G&A expenses $2.2M, net loss $5.0M. Cash position: $9.2M as of June 30, 2024. The company anticipates FDA clearance and AIMIGo launch by end of 2024.
FAQ
What is the current stock price of Heartbeam (BEAT)?
What is the market cap of Heartbeam (BEAT)?
What does HeartBeam, Inc. do?
What is unique about HeartBeam's technology?
How does HeartBeam's iCardiologist application work?
What is VECG technology?
Has HeartBeam's technology been validated?
Is HeartBeam seeking FDA clearance?
What are the benefits of HeartBeam's ECG solutions?
Can HeartBeam's technology locate a heart attack?
How is HeartBeam improving cardiac care?
Where can I find the latest news on HeartBeam, Inc.?
